Related Experiment Video
Updated: Jun 19, 2026
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Postdonation platelet counts are safe when collecting platelets with the Trima Accel using a postdonation platelet
Jessie Alex1, Beverly Roberts, Thomas Raife
1DeGowin Blood Center, Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA. jessie-alex@uiowa.edu
In December 2007, the FDA issued a guidance document recommending that apheresis cell separators be configured with a postdonation platelet count target of > or =100,000 platelets/microL. Currently, our Trima Accel apheresis cell separators are configured with a postdonation platelet count target of > or =50,000 platelets/microL. To determine the safety of our current procedure, we analyzed the postdonation platelet counts of 115 donors collected using our current procedure. All of 115 donors had postdonation platelet counts > or =100,000 platelets/microL. On the basis of predonation platelet counts, we calculated that raising the postdonation target platelet count to > or =100,000 platelets/microL would have disqualified 19 out of 225 potential platelet products. We conclude that the current postdonation platelet count target of > or =50,000 platelets/microL is safe for donors collected using the Trima Accel. Efforts to reduce the incidence of TRALI are creating challenges for the platelet supply. Increasing the postdonation platelet count target to > or =100,000 platelets/microL will reduce productivity in apheresis platelet collection and may not enhance donor safety.
In December 2007, the FDA issued a guidance document recommending that apheresis cell separators be configured with a postdonation platelet count target of > or =100,000 platelets/microL. Currently, our Trima Accel apheresis cell separators are configured with a postdonation platelet count target of > or =50,000 platelets/microL. To determine the safety of our current procedure, we analyzed the postdonation platelet counts of 115 donors collected using our current procedure. All of 115 donors had postdonation platelet counts > or =100,000 platelets/microL. On the basis of predonation platelet counts, we calculated that raising the postdonation target platelet count to > or =100,000 platelets/microL would have disqualified 19 out of 225 potential platelet products. We conclude that the current postdonation platelet count target of > or =50,000 platelets/microL is safe for donors collected using the Trima Accel. Efforts to reduce the incidence of TRALI are creating challenges for the platelet supply. Increasing the postdonation platelet count target to > or =100,000 platelets/microL will reduce productivity in apheresis platelet collection and may not enhance donor safety.
